Sitter ni här på Flashback och baissar historik, stackare är det ingen som bryr sig, eller tror att framtiden finns i backspegeln.
Biotechnology and medical technology - important with scalability
Collaboration with Kimberly-Clark is ongoing with the goal of reaching a GMP certified production line for the production of Kimberly-Clark's Transdermal Drug Delivery component (TDD). A decisive factor for Kimberly-Clark to choose NIL as production method is that it is possible to scale up to production volumes of more than 100 million units per year. During the beginning of 2017, Kimberly-Clark established a separate business unit for the TDD products called Sofusa, which also has its own website (
www.sofusa.com).
To increase cost-effectiveness in the production of various types of bio and medical devices, there is a general interest among customers to produce components on larger substrates - something that suits Obducat well, as both NIL and wet processing are needed in most cases.
Några patenthänvisningar till det svenska företaget från K-C
Åtta utav tio godkända.
PAT. NO.Title
1 9,586,044[?IMG]Method for increasing the permeability of an epithelial barrier
2 9,550,053[?IMG]Transdermal delivery of high viscosity bioactive agents
3 9,545,507[?IMG]Injection molded microneedle array and method for forming themicroneedle array
4 9,539,802[?IMG]Nanocomposite inkjet printer with integrated nanocomposite-ink factory
5 9,533,467[?IMG]Imprint material having low mold release property
6 9,526,883[?IMG]Composite microneedle array including nanostructures thereon
7 9,522,263[?IMG]Device for delivery of rheumatoid arthritis medication
8 9,522,262[?IMG]Medical devices for delivery of siRNA
:-)